FDA grants priority review for iberdomide-based myeloma regimen
1. The FDA has granted priority review for iberdomide, a first-in-class oral CELMoD designed to degrade transcription factors more effectively ...
Tag: celmod
1. The FDA has granted priority review for iberdomide, a first-in-class oral CELMoD designed to degrade transcription factors more effectively ...
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in
